Figure 1.

Response to targeted agents among patients found positive for potentially druggable alterations after next‐generation sequencing analysis in tissue or in plasma (previously screened for EGFR/ALK/ROS‐1 with standard method and found negative or not evaluable). In blue, patients who achieved partial response as best response, in green patients with stable disease as best response and in red patients who experienced disease progression as best response. Abbreviations: ex14, exon 14; mut, mutation.